Voynalovich A.S. Kolbasina R.A.

Crimean Agrotechnological University

 

The method of pharmacological contact hemostasis.

 

     The method of obtain the substance for  pharmacological contact hemostasis  which not react with blood and not seal the wound during the swelling  remains today one of the most pressing. As a base of the substance used fine-grained chitosan, added lyophilized antiseptic, mixed them and packed in tight hermitc packaging.

     This usefull model related to veterinary science and can be used for stop the  open bleeding of any severity.

      The most close to this is  patent “Clay-based hemostatic agents”  USA ¹ 7968114. Its essence is that formed  fine-grained koalin-based  powder (argil). This powder is used for stop the bleeding from open wounds, he does not interacts with the blood and  seals the wound  due to swelling during the contact with blood.

      Shortcomings of the prototype are:

1.     Hemostatic agent based on kaolin hygroscopic, that's why in case of insignificant damage of packaging he loses his properties.

2.     Hemostatic agent based on kaolin hasn't antimicrobial properties , that's why in case of semination of pathogenic microflora can develope infectional complications.

   The purpose of this usefull model is elimanation of pointed shortcomings by creating drugs in the form of powder for pharmacological contact  hemostasis , which   has not expressive hygroscopicity and has antimicrobial  properties.

     This problem is solved by obtaining the substance for pharmacological

 contact hemostasis, for this  to 10-20 gm fine-grained chitosan added 8-10 gm of freeze-dried antiseptic, for example miramistin, mixed them , and packed in tight sealed container.

     The addition of antiseptic provides:

-       disinfection of wound during infliction of contact hemostatic

-       prevention the reproduction of microorganisms in wound during long hemostasis

-        Acceleration of wound  healing  and tissues regeneration

           The use chitosan in  the composition of  substance prevents damage of preparation during the transportation  and  wear in extreme conditions, because of that it less hygroscopic than kaolin. He doesnt react with blood and body tissues , and he isnt growing medium for microorganisms.

          The embodiment of the method.

          Placed in a container  a 10 gm of fine-grained chitosan, added 5 mg freeze-dried  miramistin , after thoroughly stirred the mixture and the packed tight sealed packaging.

        Practice shows , that the substance for pharmacological contact hemostasis   allows to  speed up healing of open wounds during the stop bleeding by this preparation, and also prevents reproduction of microorganisms in the wound during long-term use of hemostatic agent. The presence of an antiseptic miramistin in the wound stimulates regeneration of tissues and inhibits the proliferation of pathogenic organisms.

        The assigned task  - elimination the disadvantages of the prototype -  confirms it all.

         The carried out patent investigations allows to make a conclusion, that the substance , similar to ours , with pointed utility model. This model has the set of distinctive features and unknown in different medical investigation

 and developments. Therefore this model is new.

        In the inventive substance  during it receive used known ingredients: chitosan,  freeze-dried  miramistin.

    Conclusion

     The new method of receive the substance for pharmacological contact hemostasis  is new model related to veterinary science and can be used for stop the open bleeding of any severity. This model  is used for stop the bleeding from open wounds, he does not interacts with the blood and  seals the wound  due to swelling during the contact with blood. Therefore this model can be used   stop the bleeding from open wounds.